Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes... I am usually very vocal on other message boards... but the NWBO board is so chock-full-of-brilliant-posters... that I'm just grateful that a dummy like me can read and learn from them.
I've been invested in NWBO since 2011... at that time Linda was just keeping the lights on by lending the company $100K a month, so I called and spoke to Alton who turned me over to Les, and I offered to keep the lights on for a month.
At the height I owned 185,000 shares at $12.50... but now I survive by following Poor Man around the country feeding on the scraps of ramen he leaves behind.
Needless to say... I'm all in... and hopeful.
p.s. I am myself from a small village about 50 miles from Naples... lived there till I was eleven... when I came to New Jersey USA.
The best ramen in your state.
https://www.msn.com/en-us/foodanddrink/foodnews/this-is-the-best-ramen-in-your-state-according-to-reviews/ss-AAQSquv?ocid=msedgdhp&pc=U531
Buon Appetito
Wonderful Post!!!!!
20+ Signs Of High Intelligence That Aren’t Always Obvious
They’re Able To Delay Gratification
There’s a link between intelligence and self-control. Pubmed published the results of a study that had participants choose between two rewards:
a smaller one that came immediately or a larger one that would come at a later date.
The study’s authors report that the people who opted to wait for the larger payoff tended to score higher on intelligence tests. These results are likely due to the fact that “delay discounting” is a process of the part of the brain involved with processing diverse information.
Just found this in an article I'm reading and thought it might be somewhat appropriate here, seeing as there is always much discussion of time here.
Having invested in NWBO in late 2011... ten years... my intelligence is growing thin.
Below is a condensed version of CaptainObvious's data ... so as to make the option exercise rate more... Obvious
From 2/7/2020 to 10/9/2021 - 262,228,093 more shares are outstanding... which I think is... outstanding
Let me explain why. - first I assume (confidently) that they are cashless warrant exercises. - Let's further ASSUME for the sake of ease of visualization that the warrant price was $.25. - Let's further ASSUME for the sake of ease of visualization that the AVERAGE share price on day of exercise was $1.50. of course it may have been somewhat more or somewhat less... but I think $1.50 is a decent AVERAGE... let's also assume for the ease of visualization that the warrants exercised is 300,000,000 rather than 262,228,093.
Now 300,000,000 warrants exercised @ 25 cents each would bring in $75 Million but since they are cashless then $75 million divided by the $1.50 average price per share at time of conversion... would be 50 million shares which NWBO would retain for itself - so although the number may show 262+ Million shares added to the outstanding shares the actual number of warrants exercised is actually ~ 320 Million warrants.
Now I'll try and explain why warrant exercised when the share price is lower is better than when they are exercised when share price is higher.
Again a lot of assumptions... 4 million warrants exercise price 25 cents - share price @ $1.50 - cost in cash $1 million. If cashless... $1,000,000 divided by $1.50 = 666,666 shares retained by NWBO... 3,333,333 shares awarded to warrant holders.
Now... 4 million warrants exercise price 25 cents - share price @ $10.00 - cost in cash $1 million. If cashless... $1,000,000 divided by $10.00 = 100,000 shares retained by NWBO... 3,900,000 shares awarded to warrant holders.
It may be somewhat confusing but the more warrants that are converted cashless at lower prices the better for NWBO and us shareholders... ASSUMING that stock price appreciates as we all hope it does.
Also I believe that if there are now 262K more outstanding shares then because they were cashless NWBO has retained approximately 60 million shares which it has added to the shelf.
10/09/21 - 889,882,057
09/09/21 - 873,117,920
08/07/21 - 872,433,236
07/03/21 - 870,142,647
06/02/21 - 853,473,626
05/07/21 - 851,564,728
04/09/21 - 842,970,418
03/09/21 - 838,233,905
02/09/21 - 831,744,500
01/12/21 - 822,825,147
12/09/20 - 820,910,073
11/09/20 - 810,613,651
10/08/20 - 776,813,079
09/14/20 - 758,362,783
08/07/20 - 731,499,352
07/09/20 - 722,256,882
06/08/20 - 699,966,420
05/07/20 - 688,978,847
02/07/20 - 627,653,964
Much has changed in the last few years... but previously Linda has???/had!!! always maintained that her intent was to go it alone with DC-Vax L... but partner DC-Vax Direct... which she said would number in the hundreds of thousands of cases.
Not sure if this has been posted... It only has 136 views.
A Review of Immunotherapy and Targeted Therapy in Glioblastoma
136 views
Jul 29, 2020
remember...
e v e r y o n e... is living longer ! ! !
My feeling is that it will be approved in the UK first along with re-imbursement - followed by Germany, then Canada and the U.S.
I also believe it may be approved in the UK and possibly Germany for newly diagnosed and recurring simultaneously AND it may well happen before the end of the year.
Merck’s new CEO Robert Davis begins, after Ken Frazier's retirement
"Rob has been instrumental in helping Merck take the right actions to adapt to the changing healthcare environment while remaining committed to investing in the scientific innovation that we expect will drive our future growth," Frazier said in the announcement. "His intellect and proven ability to define and articulate strategies that can be translated into clear and focused operational plans that lead to successful execution are also critical attributes."
Let's hope he has his eye on NWBO as a driver of their future growth.
I am 73 years old and not in good health... so I'm in favor of a buyout for ~ $10.00 - about $15 Billion up front... to take care of me... and
up to 10 year contingencies for both DcVax L and DcVax Direct with a minimum of $10 Billion payable at $1 Billion per year for the next 10 years... that will take care of my family downline.
Control number and password won't work.
Doesn't matter if you voted or not...
But you can sign in as a guest - no problem
Democrats Back Ending Carried Interest...
Would that not affect Linda and all the officers and warrant holders...????
Would it not almost double the tax on their gains???
Would that not prioritize a buyout if a buyout is on the table???
Very well said biosectinvestor
Maybe I'll give my "compare" Giovanni Caforio una telefonata...
and make him an offer he can't refuse.
40+ years ago I asked my daughter what she learned on her first day of kindergarten.
She said "I learned that a couple is 2, and a few is 3 or more"
So there... it's resolved.
p.s. she wasn't cued in on what "several" means so I guess it will remain a mystery to me.
I hope Linda has set aside 100K shares of NWBO stock, and when that stock is trading at $20.00... that she will use that $2 million to sue him and tie him up in court until he's pennyless and living in a card board box.
I believe - but I've been wrong before - that overall survival AND true progression free survival will be met.
I can't imagine that people progressed sooner but died later - those thought to progress sooner were more than likely those whose tumor was enlarged from the T-cell infiltration and were probably pseudo progressions - we'll probably find that those pseudo progressor patients were/are probably the ones that lived longest.
The axis for "probability of survival" (0.0 to 1.0) are nicely aligned… very good... BUT... the DC-Vax-L "overall survival (months)" axis has been shifted to the left by ~ 3 months... WHY???
Were those 2 axis also aligned it would clearly show the DC-Vax graph to be fairly superior to the Optune data.
https://xconomy.com/national/2019/01/16/merck-and-the-future-of-immuno-oncology-a-chat-with-roger-perlmutter/2/
Merck And The Future of Immuno-Oncology: A Chat With Roger Perlmutter
Jan 16, 2019
X: Where do you see cancer care going in the near-term?
Roger Perlmutter: You’re not going to see much monotherapy anymore, except perhaps in an adjuvant setting. In first-line [treatment of] lung cancer, which is obviously the biggest market, 70 percent of patients are [eligible for] Keytruda plus chemo, and it’ll be more later. My expectation is that Keytruda will be foundational in the treatment of the majority of malignancies, and the question will be Keytruda plus what? It’s going to be Keytruda plus X, where X is going to be a large set of different things, and it will be much more personalized, depending on the tumor type.
Dear god... he certainly seems to be zeroing in on DC Vax.
Thanxs Smokey, Doc Logic - that helped to make my Friday.
I just did a search with Firefox on DC Vax and received nothing but links to burrow into DC Vax, the trial, Northwest, Linda Liau, accelerated approval - everything one would want to find out on DC Vax and not any hint what-so-ever on Optune or Novacure... there was only a single mention of Celldex on the second page of the search.
I have never searched or gone to the Novocure's site, so I believe that those that are getting info on Optune probably have been to the novocure site where the search engine planted a cookie and is now bringing up novocure relevant information whenever a search is done on brain cancer related info.
p.s. really liked all the info that came up on my search. A wealth of info that I can refresh my memory on.
More than likely if others clean their cache and delete all cookies they would probably see all the "pure goodies" I got on DC Vax... sort of like becoming a virgin "again"
calling Numbersarefun
https://www.drugs.com/availability/generic-ranexa.html
Has a generic version of Ranexa been approved?
No. There is currently no therapeutically equivalent version of Ranexa available in the United States.
Ranexa Patent expiration dates:
May 27, 2019
? Patent use: TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE
IPCI's Ranexa ANDA was submitted after the new rules requiring ANDAs to be approved within a much shorter timeframe (2 years???) and it was never established here if it qualified for a PDUFA date.
Maybe Numbersarefun can help out with some of his deep research... if he is still around.
I once bought some LEAPS (long term options) for 10 cents each... which in a year's time became worth $4.40...
So .24 x 44 = $10.56.
Sure would love to beat that 4,400% gain in a year's time.